Chemoreflex sensitivity, exercise and beta agonists

Erasmus Hospital0 个研究点开始时间: 2007年7月11日最近更新: 2013年10月21日

适应症

试验速览

暂无简介。

•The study will include:
•-a group of 15 healthy referent sedentary participants with a resting heart rate (HR) of > 55 bpm and systolic arterial pressure > 100 mmHg.
•Participants will take a beta 2 adrenergic blocker Salbutamol and placebo perfusion of 10mg/min and of 20mg/ min for 30 min and using a randomized double-blinded crossover study design. There will be a washout period of 1 week.
•--a group of 15 healthy referent sedentary participants with a resting heart rate (HR) of > 55 bpm and systolic arterial pressure > 100 mmHg.
•Participants will take a beta 2 adrenergic blocker Fenoterol of and placebo perfusion of 5mg min for 30 min and using a randomized double-blinded crossover study design. There will be a washout period of 1 week.
•Participants will be matched of age, gender and body mass index (BMI).
•Only healthy subject will participate to the study.
•Are the trial subjects under 18?
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years)
•F.1.3.1 Number of subjects for this age range

•Asthmatic patients or subjects with chronic pneumopathy, arterial diseases or Raynaud syndrome, heart failure, myocarditis, pathological situation of mitral and aortic valve, obstructive hypertrophic cardiomyopathy, Wolff-Parkinsson-White syndrome, hypertension or hypotension, tachycardias, hyperthyroidism, hypersensibility to beta agonists will not participate.
•Great care will be ensured that the subjects do not smoke or drink coffee, tea, and other beverages containing caffeine or alcohol before the study. They will be investigated after a light breakfast.

发起方

Erasmus Hospital